Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling

British Journal of Pharmacology

Volumn 172, Issue 23, 2015, Pages 5647-5660

  Gong, Yanjun ^a   Lin, Minghui ^a   Piao, Lingjuan ^a   Li, Xinzhi ^b   Yang, Fei ^c   Zhang, Jian ^a   Xiao, Bing ^a   Zhang, Qingli ^a   Song, Wen Liang ^d   Yin, Huiyong ^a   Zhu, Li ^c   Funk, Colin D ^b   Yu, Ying ^a  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b QUEEN S UNIVERSITY   (Canada)

^c SOOCHOW UNIVERSITY   (China)

^d BRIDGEPORT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELL ADHESION MOLECULE; CHOLESTEROL; CYCLOOXYGENASE 1; CYTOKINE; FATTY ACID DERIVATIVE; FISH OIL; OMEGA 3 FATTY ACID; RESOLVIN E1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHLORIDE; FERRIC CHLORIDE; FERRIC ION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERITIS; ARTERY INJURY; ARTICLE; BLOOD VESSEL REACTIVITY; CAROTID ARTERY THROMBOSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; FEMORAL ARTERY; HYPERPLASIA; INFLAMMATORY CELL; LIPID MEMBRANE; MALE; MONOTHERAPY; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESOLVIN E1 BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CHEMICALLY INDUCED; DIETARY SUPPLEMENT; DOSE RESPONSE; DRUG EFFECTS; INBRED MOUSE STRAIN; PATHOLOGY; PHOTOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VASCULAR SYSTEM INJURIES;

ANIMALS; ASPIRIN; CHLORIDES; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMORAL ARTERY; FERRIC COMPOUNDS; FISH OILS; MALE; MICE; MICE, INBRED STRAINS; PHOTOCHEMICAL PROCESSES; PLATELET AGGREGATION; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS; VASCULAR SYSTEM INJURIES;

EID: 84949529000     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12986     Document Type: Article

References (65)

1. Abdolahi A, Georas SN, Brenna JT, Cai X, Thevenet-Morrison K, Phipps RP, et al. (2014). The effects of aspirin and fish oil consumption on lysophosphatidylcholines and lysophosphatidic acids and their correlates with platelet aggregation in adults with diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 90: 61-68.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, et al. (2005). Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102: 7671-7676.
5. Astrup A, (2014). Yogurt and dairy product consumption to prevent cardiometabolic diseases: epidemiologic and experimental studies. Am J Clin Nutr 99 (5 Suppl.): 1235S-1242S.
6. Block RC, Kakinami L, Jonovich M, Antonetti I, Lawrence P, Meednu N, et al. (2012). The combination of EPA + DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans. Prostaglandins Leukot Essent Fatty Acids 87: 143-151.
7. Buckley CD, Gilroy DW, Serhan CN, (2014). Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 40: 315-327.
8. Butcher EC, (1991). Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67: 1033-1036.
9. Calder PC, (2014). Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta. doi: 10.1016/j.bbalip.2014.08.010
10. Calder PC, Grimble RF, (2002). Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr 56: S14-S19.
11. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, et al. (2011). Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Intervent 4: 180-187.
12. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, FitzGerald GA, (2006). Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116: 1391-1399.
13. Dillinger JG, Drissa A, Sideris G, Bal dit Sollier C, Voicu S, Manzo Silberman S, et al. (2012). Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. Am Heart J 164: 600-606 e601.
14. Dona M, Fredman G, Schwab JM, Chiang N, Arita M, Goodarzi A, et al. (2008). Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood 112: 848-855.
15. El Kebir D, Gjorstrup P, Filep JG, (2012). Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc Natl Acad Sci U S A 109: 14983-14988.
16. Faggin E, Puato M, Chiavegato A, Franch R, Pauletto P, Sartore S, (2000). Fish oil supplementation prevents neointima formation in nonhypercholesterolemic balloon-injured rabbit carotid artery by reducing medial and adventitial cell activation. Arterioscler Thromb Vasc Biol 20: 152-163.
17. Floyd CN, Ferro A, (2014). Mechanisms of aspirin resistance. Pharmacol Ther 141: 69-78.
18. Fredman G, Van Dyke TE, Serhan CN, (2010). Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscl Throm Vas 30: 2005-2013.
19. Gajos G, Rostoff P, Undas A, Piwowarska W, (2010). Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after PCI to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol 55: 1671-1678.
20. Gouya G, Arrich J, Wolzt M, Huber K, Verheugt FW, Gurbel PA, et al. (2014). Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke 45: 492-503.
21. Grimsgaard S, Bonaa KH, Hansen JB, Nordoy A, (1997). Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 66: 649-659.
22. Grove EL, Hvas AM, Larsen SB, Mortensen SB, Kristensen SD, (2011). Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease: reply to a rebuttal. J Thromb Haemost 9: 889-890.
23. Hanke AA, Roberg K, Monaca E, Sellmann T, Weber CF, Rahe-Meyer N, et al. (2010). Impact of platelet count on results obtained from multiple electrode platelet aggregometry (multiplate). Eur J Med Res 15: 214-219.
24. Harris WS, (1997). n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65 (5 Suppl.): 1645S-1654S.
25. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ, (2008). Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197: 12-24.
26. Harris WS, Dayspring TD, Moran TJ, (2013). Omega-3 fatty acids and cardiovascular disease: new developments and applications. Postgrad Med 125: 100-113.
27. Haworth O, Cernadas M, Levy BD, (2011). NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. J Immunol 186: 6129-6135.
28. Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R, et al. (2010). Aspirin-triggered lipoxin and Resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 177: 2116-2123.
29. Inoue T, Node K, (2009). Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 73: 615-621.
30. Kim TH, Kim GD, Jin YH, Park YS, Park CS, (2012). Omega-3 fatty acid-derived mediator, Resolvin E1, ameliorates 2,4-dinitrofluorobenzene-induced atopic dermatitis in NC/Nga mice. Int Immunopharmacol 14: 384-391.
31. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
32. Kris-Etherton PM, Harris WS, Appel LJ, (2002). Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106: 2747-2757.
33. Larson MK, Tormoen GW, Weaver LJ, Luepke KJ, Patel IA, Hjelmen CE, et al. (2013). Exogenous modification of platelet membranes with the omega-3 fatty acids EPA and DHA reduces platelet procoagulant activity and thrombus formation. Am J Physiol Cell Physiol 304: C273-C279.
34. Lev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, et al. (2010). Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol 55: 114-121.
35. Livak KJ, Schmittgen TD, (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
36. Marangoni F, Poli A, (2013). Clinical pharmacology of n-3 polyunsaturated fatty acids: non-lipidic metabolic and hemodynamic effects in human patients. Atheroscler Suppl 14: 230-236.
37. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
38. Mijajlovic MD, Shulga O, Bloch S, Covickovic-Sternic N, Aleksic V, Bornstein NM, (2013). Clinical consequences of aspirin and clopidogrel resistance: an overview. Acta Neurol Scand 128: 213-219.
39. Miller PE, Van Elswyk M, Alexander DD, (2014). Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens 27: 885-896.
40. Miyahara T, Runge S, Chatterjee A, Chen M, Mottola G, Fitzgerald JM, et al. (2013). D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J 27: 2220-2232.
41. Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, et al. (2009). Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 183: 2089-2096.
42. Ogawa N, Kobayashi Y, (2009). Total synthesis of Resolvin E1. Tetrahedron Lett 50: 6079-6082.
43. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. (2010). GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687-698.
44. Owens AP, Lu Y, Whinna HC, Gachet C, Fay WP, Mackman N, (2011). Towards a standardization of the murine ferric chloride-induced carotid arterial thrombosis model. J Thromb Haemost 9: 1862-1863.
45. Pakala R, Benedict C, (1999). Eicosapentaenoic acid and docosahexaenoic acid selectively attenuate U46619-induced smooth muscle cell proliferation. Lipids 34: 915-920.
46. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
47. Petrich BG, Fogelstrand P, Partridge AW, Yousefi N, Ablooglu AJ, Shattil SJ, et al. (2007). The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation. J Clin Invest 117: 2250-2259.
48. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. (2010). Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation (vol 33, pg 1395, 2010). Diabetes Care 33: 2129-2131.
49. de Roos B, Mavrommatis Y, Brouwer IA, (2009). Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br J Pharmacol 158: 413-428.
50. Sasaki J, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, et al. (2012). Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). J Atheroscler Thromb 19: 194-204.
51. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, et al. (1988). Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 318: 1714-1719.
52. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K, (2000). Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192: 1197-1204.
53. Serhan CN, Chiang N, Van Dyke TE, (2008). Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361.
54. Shah PK, (2003). Inflammation, neointimal hyperplasia, and restenosis: as the leukocytes roll, the arteries thicken. Circulation 107: 2175-2177.
55. Smith WL, (2005). Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol 17: 174-182.
56. Spite M, Serhan CN, (2010). Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 107: 1170-1184.
57. Steinhubl SR, Berger PB, (2009). Aspirin following PCI: too much of a good thing? Eur Heart J 30: 882-884.
58. Tomasdottir V, Vikingsson A, Freysdottir J, Hardardottir I, (2013). Dietary fish oil reduces the acute inflammatory response and enhances resolution of antigen-induced peritonitis. J Nutr Biochem 24: 1758-1765.
59. Welt FG, Rogers C, (2002). Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22: 1769-1776.
60. Yan S, Zhang Q, Zhong X, Tang J, Wang Y, Yu J, et al. (2014). I Prostanoid Receptor-mediated inflammatory pathway promotes hepatic gluconeogenesis through activation of PKA and inhibition of AKT. Diabetes 63: 2911-2923.
61. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW, et al. (2004). Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110: 301-308.
62. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. (2007). Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369: 1090-1098.
63. Yu Y, Cheng Y, Fan JJ, Chen XS, Klein-Szanto A, Fitzgerald GA, et al. (2005). Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J Clin Invest 115: 986-995.
64. Zhang G, Sun Q, Hu FB, Ye XW, Yu ZJ, Zong G, et al. (2012). Erythrocyte n-3 fatty acids and metabolic syndrome in middle-aged and older Chinese. J Clin Endocr Metab 97: E973-E977.
65. Zhang J, Zou FF, Tang J, Zhang QQ, Gong YJ, Wang QS, et al. (2013). Cyclooxygenase-2-derived prostaglandin e-2 promotes injury-induced vascular neointimal hyperplasia through the e-prostanoid 3 receptor. Circ Res 113: 104-114.